Drug patents opposed in 2023
Drug patents opposed in 2023 at the European Patent Office (EPO)
| Patent Number | Patent Title | Company | Recent Opposition Date | Recent Opposition By | Activity Alert |
|---|---|---|---|---|---|
| EP3954690B1 | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide | ACERTA PHARMA BV |
29 Dec, 2023
(Expiration: Jul, 2036)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3439647B1 | Method For Reducing Or Preventing Global Developmental Delay In Children | NUTRICIA NV |
21 Dec, 2023
(Expiration: Apr, 2036)
|
SOCIT DES PRODUITS NESTL
| |
| EP3416658B1 | Human Functional Corneal Endothelial Cell And Application Thereof | KYOTO PREFECTURAL PUBLIC UNIV CORP |
20 Dec, 2023
(Expiration: Feb, 2037)
|
VO
| |
| EP2658520B1 | Leave-In Conditioning Composition For Hair | KAO GERMANY GMBH |
18 Dec, 2023
(Expiration: Dec, 2031)
|
HENKEL
| |
| EP3290043B1 | Enzyme-Treated Milk Product, Method For Producing Same, Composition, And Product | SAISEI PHARMA CO LTD |
15 Dec, 2023
(Expiration: May, 2036)
|
NUTRICIA
| |
| EP3645553B1 | Tropism-Modified Recombinant Viral Particles And Uses Thereof For The Targeted Introduction Of Genetic Material Into Human Cells | REGENERON PHARMACEUTICALS INC |
15 Dec, 2023
(Expiration: Jun, 2038)
|
STRAWMAN
(and 1 more)
| |
| EP3598967B1 | Personal Cleansing Compositions, Methods And Uses | PROCTER AND GAMBLE CO |
15 Dec, 2023
(Expiration: Jul, 2038)
|
UNILEVER UNILEVER
| |
| EP3179986B1 | Dry Powder Formulations For Inhalation | VECTURA INC |
14 Dec, 2023
(Expiration: Jul, 2035)
|
GENERICS UK
| |
| EP3727599B8 | Composition For Dyeing Keratin Fibers Containing A Combination Of A P-Phenylene Derivative And 2,7-Naphthalenediol And Use Thereof For Reducing A Yellow Tinge In A Hairstyle | LABORATOIRE BIOSTHETIQUE KOSMETIK & CO KG GMBH |
14 Dec, 2023
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP3512505B1 | Vildagliptin Pharmaceutical Compositions | GALENICUM HEALTH SL |
13 Dec, 2023
(Expiration: Sep, 2037)
|
KNPP PARTGMBB
(and 1 more)
| |
| EP4070788B1 | Pharmaceutical Formulations | GILEAD SCIENCES INC |
11 Dec, 2023
(Expiration: Jun, 2036)
|
ZENTIVA
| |
| EP3294283B1 | Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure | NOVARTIS AG |
08 Dec, 2023
(Expiration: May, 2036)
|
ZENTIVA
(and 14 more)
| |
| EP4023755B1 | Artificial Nucleic Acid Molecules For Improved Protein Expression | CUREVAC SE |
06 Dec, 2023
(Expiration: Dec, 2035)
|
BIONTECH
(and 3 more)
| |
| EP3402573B1 | Composition Containing Amino Acids | INDIVIDUAL |
01 Dec, 2023
(Expiration: Jan, 2037)
|
ARLA FOODS AMBA
(and 1 more)
| |
| EP2981272B1 | Microporous Zirconium Silicate And Diuretics For The Reduction Of Potassium And Treatment Of Chronic Kidney And/Or Chronic Heart Disease | ZS PHARMA INC |
01 Dec, 2023
(Expiration: Apr, 2034)
|
GENERICS UK
(and 1 more)
| |
| EP4066819B1 | Small Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
30 Nov, 2023
(Expiration: Aug, 2031)
|
BIONTECH
(and 3 more)
| |
| EP3686211B1 | Process For Efficient Purification Of Neutral Human Milk Oligosaccharides (Hmos) From Microbial Fermentation | CHR HANSEN HMO GMBH |
30 Nov, 2023
(Expiration: Dec, 2034)
|
GREAVES BREWSTER
(and 1 more)
| |
| EP3680249B1 | Process For Efficient Purification Of Neutral Human Milk Oligosaccharides (Hmos) From Microbial Fermentation | CHR HANSEN HMO GMBH |
30 Nov, 2023
(Expiration: Dec, 2034)
|
GREAVES BREWSTER
(and 1 more)
| |
| EP3042669B1 | Antitumor Agent And Antitumor Effect Enhancer | TAIHO PHARMACEUTICAL CO LTD |
29 Nov, 2023
(Expiration: Sep, 2034)
|
CAMULON
(and 1 more)
| |
| EP4070787B1 | Pharmaceutical Formulations | GILEAD SCIENCES INC |
29 Nov, 2023
(Expiration: Jun, 2036)
|
ZENTIVA
| |
| EP3880160B1 | Dentifrice Containing Sodium Bicarbonate And Stannous Fluoride | COLGATE PALMOLIVE CO |
27 Nov, 2023
(Expiration: Dec, 2039)
|
HALEON UK
| |
| EP3302507B1 | Diagnostic Methods For T Cell Therapy | US DEPARTMENT OF HEALTH AND HUMAN SERVICES |
22 Nov, 2023
(Expiration: May, 2036)
|
BOULT WADE TENNANT
| |
| EP3395383B1 | Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo | REGEN LAB SA |
22 Nov, 2023
(Expiration: Aug, 2027)
|
ESTAR
| |
| EP3811943B1 | Compound For Use In The Treatment Of Ocular Disorders | AERIE PHARMACEUTICALS INC |
22 Nov, 2023
(Expiration: Mar, 2034)
|
GENERICS UK
(and 2 more)
| |
| EP3880197B1 | Methods Of Treatment For Cystic Fibrosis | VERTEX PHARMACEUTICALS INC |
22 Nov, 2023
(Expiration: Nov, 2039)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP3393510B1 | Zika Virus Vaccine | VALNEVA AUSTRIA GMBH |
21 Nov, 2023
(Expiration: Dec, 2036)
|
MAIWALD
| |
| EP3534939B1 | Vaccine Against Porcine Parvovirus And Porcine Reproductive And Respiratory Syndrome Virus And Methods Of Production Thereof | BOEHRINGER INGELHEIM VETMEDICA GMBH |
21 Nov, 2023
(Expiration: Nov, 2037)
|
ZOETIS SERVICES
| |
| EP3666797B1 | Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) | AMGEN INC |
10 Nov, 2023
(Expiration: Aug, 2028)
|
SANOFI AVENTIS DEUTSCHLAND
(and 1 more)
| |
| EP3000467B1 | Treatment Regimen Utilizing Neratinib For Breast Cancer | WYETH LLC |
03 Nov, 2023
(Expiration: Mar, 2030)
|
HEXAL
(and 2 more)
| |
| EP2575744B1 | Skin Treatment Composition | UNILEVER GLOBAL IP LTD |
27 Oct, 2023
(Expiration: May, 2031)
|
BEIERSDORF
| |
| EP4010082B1 | Multispecific Anti-Tcr Delta Variable 1 Antibodies | GAMMADELTA THERAPEUTICS LTD |
25 Oct, 2023
(Expiration: Aug, 2041)
|
MARGARET DIXON
| |
| EP3551160B1 | Flexible Solid Cosmetic Composition Comprising Sulfonate Anionic Surfactants, Fatty Esters And Fatty Alcohols, And Cosmetic Treatment Method | LOREAL SA |
23 Oct, 2023
(Expiration: Nov, 2037)
|
HENKEL
| |
| EP3805248B1 | Process For Concentration Of Antibodies And Therapeutic Products Thereof | NOVARTIS AG |
18 Oct, 2023
(Expiration: Sep, 2025)
|
KILBURN & STRODE
(and 1 more)
| |
| EP3318259B1 | Stable Pharmaceutical Composition For Oral Administration | ASTELLAS PHARMA INC |
11 Oct, 2023
(Expiration: Jul, 2036)
|
GENERICS UK
(and 1 more)
| |
| EP4043040B1 | Small Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
11 Oct, 2023
(Expiration: Aug, 2031)
|
JG OPPOSITIONS
(and 3 more)
| |
| EP2482812B1 | Therapeutic Uses Of Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
11 Oct, 2023
(Expiration: Oct, 2030)
|
LUIGI
(and 2 more)
| |
| EP4011915B8 | Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist | SANOFI BIOTECHNOLOGY SAS |
11 Oct, 2023
(Expiration: Aug, 2033)
|
LUIGI
| |
| EP3264923B1 | Compositions For Use In The Prevention Or Treatment Of Gastrointestinal Infections/Inflammations In Infants Or Young Children | SOCIETE DES PRODUITS NESTLE SA |
10 Oct, 2023
(Expiration: Mar, 2036)
|
FRIESLANDCAMPINA NEDERLAND
(and 1 more)
| |
| EP3362055B1 | Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
06 Oct, 2023
(Expiration: Oct, 2036)
|
SANDOZ
(and 1 more)
| |
| EP3897726B1 | Dietary Butyrate | SOCIETE DES PRODUITS NESTLE SA |
04 Oct, 2023
(Expiration: Dec, 2039)
|
AAK PUBL
| |
| EP3937662B1 | Non-Tobacco Oral Nicotine Pouch Composition | PHILIP MORRIS PRODUCTS SA |
04 Oct, 2023
(Expiration: Nov, 2040)
|
NICOVENTURES TRADING
| |
| EP3122426B1 | Method Of Treating Cancer Using Selective Estrogen Receptor Modulators | DUKE UNIVERSITY |
04 Oct, 2023
(Expiration: Mar, 2035)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP4019041B1 | Toxicity Management For Anti-Tumor Activity Of Cars | CHILDRENS HOSPITAL OF PHILADELPHIA CHOP |
28 Sep, 2023
(Expiration: Jul, 2033)
|
PATENT BOUTIQUE
(and 2 more)
| |
| EP4066855B1 | Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
28 Sep, 2023
(Expiration: Aug, 2031)
|
THOMANN
(and 3 more)
| |
| EP2968201B1 | Enhanced Drug Delivery From Adhesives | AVERY DENNISON CORP |
27 Sep, 2023
(Expiration: Mar, 2034)
|
BIOCOM SYSTEMS
| |
| EP3464277B1 | Pegylated Carfilzomib Compounds | AMGEN INC |
27 Sep, 2023
(Expiration: May, 2037)
|
LUIGI
| |
| EP3581650B1 | Factor Ix Polypeptide Mutant, Its Uses And A Method For Its Production | UNIQURE BIOPHARMA BV |
27 Sep, 2023
(Expiration: Sep, 2029)
|
PFIZER
| |
| EP4008357B1 | Small Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
22 Sep, 2023
(Expiration: Aug, 2031)
|
SANOFI
(and 3 more)
| |
| EP3285776B1 | Methods Of Treating Bacterial Infections | MELINTA THERAPEUTICS INC |
21 Sep, 2023
(Expiration: Apr, 2036)
|
GENERICS UK
| |
| EP3883603B1 | A Vaccine For Protection Against Streptococcus Suis | INTERVET INTERNATIONAL BV |
19 Sep, 2023
(Expiration: Nov, 2039)
|
CEVA SANTE ANIMALE
| |
| EP4066857B1 | Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
19 Sep, 2023
(Expiration: Aug, 2031)
|
SANOFI
(and 3 more)
| |
| EP3318281B1 | Highly Purified Sugars And Sugar Compositions | CORIOLIS PHARMA RESEARCH GMBH |
15 Sep, 2023
(Expiration: Nov, 2036)
|
GRNECKER PATENT UND RECHTSANWLTE PARTG MBB
| |
| EP3634468B1 | Solid Compositions For Oral Administration | NOVO NORDISK AS |
14 Sep, 2023
(Expiration: Jun, 2038)
|
GENERICS UK
| |
| EP3886795B1 | Composition For Keratin Fibers Comprising A Direct Dye | LOREAL SA |
14 Sep, 2023
(Expiration: Nov, 2039)
|
HENKEL
| |
| EP3517539B1 | Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
14 Sep, 2023
(Expiration: Jul, 2032)
|
KNPP PARTGMBB
(and 2 more)
| |
| EP3138415B1 | Metabolic Imprinting Effects Of Specifically Designed Lipid Component | NUTRICIA NV |
14 Sep, 2023
(Expiration: Jun, 2032)
|
SOCIT DES PRODUITS NESTL
| |
| EP3445407B1 | Compositions And Methods Of Cellular Immunotherapy | CRAGE MEDICAL CO LTD |
13 Sep, 2023
(Expiration: Apr, 2037)
|
MURGITROYD
(and 1 more)
| |
| EP3119423B1 | Treatment Of Cancer Using Chimeric Antigen Receptor | NOVARTIS AG |
13 Sep, 2023
(Expiration: Mar, 2035)
|
MURGITROYD
(and 2 more)
| |
| EP3471766B1 | Recombinant Non-Pathogenic Marek'S Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus And Infectious Bursal Disease Virus Antigens | INTERVET INTERNATIONAL BV |
12 Sep, 2023
(Expiration: Jun, 2037)
|
BOEHRINGER INGELHEIM VETMEDICA
| |
| EP3694607B1 | Compact Shampoo Composition | PROCTER AND GAMBLE CO |
12 Sep, 2023
(Expiration: Oct, 2038)
|
HENKEL
| |
| EP3738585B1 | Direct Compression Formulation And Process | NOVARTIS AG |
11 Sep, 2023
(Expiration: Jan, 2025)
|
HERZOG PATENTANWALTS
| |
| EP3532016B1 | Method Of Preparing A Product Composition Comprising A Discrete Particle And An Aqueous Base Composition | PROCTER AND GAMBLE CO |
07 Sep, 2023
(Expiration: Apr, 2038)
|
HENKEL
| |
| EP3877395B1 | Industrial Process For The Preparation Of High Purity Estetrol | RICHTER GEDEON NYRT |
07 Sep, 2023
(Expiration: Sep, 2040)
|
INDUSTRIALE CHIMICA
| |
| EP3752510B1 | Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making Them | VERTEX PHARMACEUTICALS INC |
07 Sep, 2023
(Expiration: Feb, 2039)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP4066856B1 | Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
07 Sep, 2023
(Expiration: Aug, 2031)
|
WEICKMANN & WEICKMANN PARTMBB
(and 3 more)
| |
| EP3355919B1 | Combination Therapy Using Inhibitors Of Human Growth And Differentiation Factor 15 (Gdf-15) And Immune Checkpoint Blockers | JULIUS MAXIMILIANS UNIVERSITAET WUERZBURG |
06 Sep, 2023
(Expiration: Sep, 2036)
|
PFIZER
| |
| EP2635537B1 | Lithium Silicate Glasses Or Glass Ceramics, Method For Production Thereof And Use Thereof | FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV |
30 Aug, 2023
(Expiration: Jun, 2031)
|
IVOCLAR VIVADENT
| |
| EP2566469B1 | Combination Therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
30 Aug, 2023
(Expiration: May, 2031)
|
SANDOZ
(and 1 more)
| |
| EP3067043B1 | Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor | NOVARTIS AG |
30 Aug, 2023
(Expiration: Nov, 2028)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 5 more)
| |
| EP3516966B1 | A Concentrated Krill Protein Hydrolysate Fraction | RIMFROST TECHNOLOGIES AS |
29 Aug, 2023
(Expiration: Sep, 2029)
|
AKER BIOMARINE ANTARCTIC
| |
| EP3578175B1 | Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound | AMGEN INC |
29 Aug, 2023
(Expiration: Sep, 2024)
|
ARROW GENERIQUES PUREN PHARMA
(and 6 more)
| |
| EP3920970B1 | Method For Treating Checkpoint Inhibitors Induced Adverse Events | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS APHP |
23 Aug, 2023
(Expiration: Feb, 2040)
|
JG OPPOSITIONS
| |
| EP3555064B9 | Glp-1 Receptor Agonists And Uses Thereof | PFIZER INC |
23 Aug, 2023
(Expiration: Dec, 2037)
|
MARGARET DIXON
| |
| EP3452050B1 | Composition Comprising Hmos For The Treatment Of Non-Infectious Diarrhoea | GLYCOM AS |
23 Aug, 2023
(Expiration: May, 2037)
|
WEICKMANN & WEICKMANN PARTMBB
| |
| EP3459528B1 | Preparation Of Solid Dosage Forms Comprising Antibodies By Solution/Suspension Layering | TILLOTTS PHARMA AG |
22 Aug, 2023
(Expiration: Sep, 2037)
|
HEIROTH
| |
| EP3421034B1 | Composite Capsule Preparation Containing Tadalafil And Tamsulosin And Having Improved Stability And Elution Rate | HANMI PHARMACEUTICAL CO LTD |
16 Aug, 2023
(Expiration: Mar, 2037)
|
GENERICS UK
| |
| EP3283058B1 | Ribociclib Tablet | NOVARTIS AG |
15 Aug, 2023
(Expiration: Apr, 2036)
|
ADALVO
(and 2 more)
| |
| EP3219306B1 | Composition For Preventing And Treating Neuodegenerative Diseases Ad Cognitive Disorders | NEURAXPHARM ITALY SPA |
14 Aug, 2023
(Expiration: Mar, 2037)
|
SIFI
| |
| EP3658141B1 | Treating Pathological Conditions By Direct And Indirect Targeting Of Sirpa - Cd47 Interaction | LEIDS UNIVERSITAIR MEDISCH CENTRUM LUMC |
11 Aug, 2023
(Expiration: Jul, 2038)
|
STRAWMAN
| |
| EP3302437B8 | Stable Cannabinoid Formulations | RADIUS PHARMACEUTICALS INC |
09 Aug, 2023
(Expiration: May, 2036)
|
CARDIOL THERAPEUTICS
| |
| EP3256003B1 | Lipid Extraction Processes | AKER BIOMARINE ANTARCTIC AS |
08 Aug, 2023
(Expiration: Feb, 2036)
|
RIMFROST
| |
| EP3509581B1 | Formulations Of (R | JAZZ PHARMACEUTICALS IRELAND LTD |
08 Aug, 2023
(Expiration: Sep, 2037)
|
SANDOZ
| |
| EP2838548B1 | Hla Class Ii Deficient Cells, Hla Class I Deficient Cells Capable Of Expressing Hla Class Ii Proteins, And Uses Thereof | UNIVERSITY OF WASHINGTON CENTER FOR COMMERCIALIZATION |
03 Aug, 2023
(Expiration: Mar, 2033)
|
JAMES POOLE
| |
| EP3458083B1 | Polynucleotides Encoding Interleukin-12 (Il12) And Uses Thereof | MODERNATX INC |
02 Aug, 2023
(Expiration: May, 2037)
|
BIONTECH
(and 1 more)
| |
| EP3463345B1 | Pharmaceutical Combinations | ARRAY BIOPHARMA INC |
01 Aug, 2023
(Expiration: Jun, 2037)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
(and 1 more)
| |
| EP2861226B1 | Nutritional Product | VITAFLO INTERNATIONAL LTD |
01 Aug, 2023
(Expiration: Jun, 2033)
|
NUTRICIA
(and 1 more)
| |
| EP3096781B1 | Agents For Use In The Treatment Of Retinal Inflammation | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS |
01 Aug, 2023
(Expiration: Jan, 2035)
|
STRAWMAN
| |
| EP3607069B1 | Products And Compositions | SILENCE THERAPEUTICS GMBH |
31 Jul, 2023
(Expiration: Apr, 2038)
|
AMMELBURG
| |
| EP3684381B8 | Production Of Extracellular Vesicles In Single-Cell Suspension Using Chemically-Defined Cell Culture Media | CODIAK BIOSCIENCES INC |
31 Jul, 2023
(Expiration: Sep, 2038)
|
STRAWMAN
| |
| EP3883606B9 | Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody | JANSSEN BIOTECH INC |
27 Jul, 2023
(Expiration: Sep, 2039)
|
CAMULON
(and 1 more)
| |
| EP3352768B1 | Methods Of Promoting Hepatic Regeneration | INTERCEPT PHARMACEUTICALS INC |
27 Jul, 2023
(Expiration: Sep, 2036)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 2 more)
| |
| EP3723722B1 | Thickening And Stabilising System Of Natural Origin Suitable, In Particular, For Preparing Cosmetic Products | ROQUETTE FRERES SA |
26 Jul, 2023
(Expiration: Dec, 2038)
|
BEIERSDORF
(and 1 more)
| |
| EP3578173B1 | Dosage Form Containing Oxycodone And Naloxone | EURO CELTIQUE SA |
26 Jul, 2023
(Expiration: Feb, 2026)
|
ETHYPHARM
(and 4 more)
| |
| EP3345607B1 | Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or Agonist | OSSIFI MAB LLC |
26 Jul, 2023
(Expiration: Dec, 2027)
|
HIGHTONE MANAGEMENT
(and 3 more)
| |
| EP3512545B1 | A Novel Method For Stabilization Of A Biopharmaceutical Drug Product During Processing | LEUKOCARE AG |
26 Jul, 2023
(Expiration: Sep, 2037)
|
MAIWALD
| |
| EP3554536B1 | Recombinant Hvt Vectors Expressing Multiple Antigens Of Avian Pathogens, And Vaccines Comprising Them | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC |
26 Jul, 2023
(Expiration: Dec, 2037)
|
TER MEER STEINMEISTER & PARTNER PATENTANWLTE MBB
| |
| EP2578231B1 | Antitumor T Cell Response Enhancer | HOKKAIDO UNIVERSITY NUC |
25 Jul, 2023
(Expiration: May, 2031)
|
GEDEON RICHTER PHARMA
| |
| EP3035958B1 | Porcine Circovirus Type 2 (Pcv2) Subunit Vaccine | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC |
25 Jul, 2023
(Expiration: Aug, 2034)
|
VIRBAC
(and 1 more)
| |
| EP3678649B8 | Intranasal Epinephrine Formulations And Methods For The Treatment Of Disease | AEGIS THERAPEUTICS LLC |
24 Jul, 2023
(Expiration: Feb, 2039)
|
AERA
| |
| EP3727300B1 | An Antimicrobial Composition | UNILEVER GLOBAL IP LTD |
21 Jul, 2023
(Expiration: Dec, 2038)
|
BEIERSDORF
| |
| EP3972552B1 | Cosmetic Compositions For Soft-Focus | UNILEVER GLOBAL IP LTD |
21 Jul, 2023
(Expiration: May, 2040)
|
LOREAL
| |
| EP3530722B1 | Detergent Composition | SHISEIDO CO LTD |
19 Jul, 2023
(Expiration: Sep, 2037)
|
HENKEL
| |
| EP2997141B1 | Cd19 Specific Chimeric Antigen Receptor And Uses Thereof | CELLECTIS SA |
12 Jul, 2023
(Expiration: May, 2034)
|
ACOPAT
| |
| EP2959894B1 | S1P Receptor Modulators For Treating Multiple Sclerosis | NOVARTIS AG |
12 Jul, 2023
(Expiration: Jun, 2027)
|
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTEL
(and 22 more)
| |
| EP3941593B1 | An Antiperspirant Composition Comprising Reactive Salts | UNILEVER GLOBAL IP LTD |
12 Jul, 2023
(Expiration: Mar, 2040)
|
LOREAL
| |
| EP4005592B1 | Virion-Like Delivery Particles For Self-Replicating Rna Molecules | GLAXOSMITHKLINE BIOLOGICALS SA |
12 Jul, 2023
(Expiration: Jul, 2031)
|
MARGARET DIXON
(and 1 more)
| |
| EP3609497B1 | Combination Therapy For Prostate Cancer | JANSSEN PHARMACEUTICA NV |
11 Jul, 2023
(Expiration: Apr, 2038)
|
SANDOZ
(and 2 more)
| |
| EP3324979B1 | Infectious Disease Vaccines | MODERNATX INC |
10 Jul, 2023
(Expiration: Jul, 2036)
|
BIONTECH
| |
| EP3157629B1 | Methods Of Cancer Treatment With Antagonists Against Pd-1 And Pd-L1 In Combination With Radiation Therapy | MEDIMMUNE LTD |
04 Jul, 2023
(Expiration: Jun, 2035)
|
TESARO
| |
| EP3302404B1 | Microcapsules With High Deposition On Surfaces | FIRMENICH SA |
28 Jun, 2023
(Expiration: Jun, 2036)
|
GIVAUDAN
| |
| EP3775125B1 | Cleaning Composition | UNILEVER GLOBAL IP LTD |
26 Jun, 2023
(Expiration: Apr, 2039)
|
BEIERSDORF
(and 1 more)
| |
| EP3324936B1 | Method For Producing A Bortezomib Ester Solution | STADA ARZNEIMITTEL AG |
26 Jun, 2023
(Expiration: Jul, 2036)
|
STRAWMAN
(and 5 more)
| |
| EP3585726B1 | Systems And Methods For Generating Nitric Oxide | THIRD POLE INC |
20 Jun, 2023
(Expiration: Feb, 2038)
|
BEYOND AIR
| |
| EP2635282B1 | Compositions And Methods For Treating Myelofibrosis | IMPACT BIOMEDICINES INC |
19 Jun, 2023
(Expiration: Nov, 2031)
|
ELKINGTON AND FIFE
| |
| EP3809884B1 | Nicotine Pouch Product | PHILIP MORRIS PRODUCTS SA |
16 Jun, 2023
(Expiration: Jun, 2040)
|
BRITISH AMERICAN TOBACCO INVESTMENTS
| |
| EP3310760B8 | Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders | ARENA PHARMACEUTICALS INC |
14 Jun, 2023
(Expiration: Jun, 2036)
|
SANDOZ
(and 1 more)
| |
| EP2954787B1 | Liquid Enteral Nutritional Composition With A Low Monovalent Metal Ion Content | NUTRICIA NV |
13 Jun, 2023
(Expiration: Jun, 2030)
|
ARLA FOODS AMBA
(and 3 more)
| |
| EP3897543B1 | Deposition System For Hair | UNILEVER GLOBAL IP LTD |
13 Jun, 2023
(Expiration: Dec, 2039)
|
HENKEL
| |
| EP3269386B1 | Aluminium Compounds For Use In Therapeutics And Vaccines | VALNEVA AUSTRIA GMBH |
13 Jun, 2023
(Expiration: Dec, 2032)
|
MAIWALD
| |
| EP3798214B1 | Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INC |
12 Jun, 2023
(Expiration: Oct, 2035)
|
GENERICS UK
| |
| EP3880802B1 | Improved T Cell Manufacturing Process | CELGENE CORP |
07 Jun, 2023
(Expiration: Nov, 2039)
|
BOULT WADE TENNANT
| |
| EP3129044B1 | Pharmaceutical Composition Against Chronic Bacterial Infections | LYSANDO AG |
07 Jun, 2023
(Expiration: Apr, 2035)
|
STRAWMAN
(and 1 more)
| |
| EP3661503B1 | Antifungal Agents With Enhanced Activity In Acidic Ph | SCYNEXIS CHEMISTRY AND AUTOMATION INC |
07 Jun, 2023
(Expiration: Jul, 2038)
|
SYNTHON
(and 1 more)
| |
| EP2849754B1 | A Xanthine Derivative As Dpp-4 Inhibitor For Use In The Treatment Of Sirs And/Or Sepsis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
05 Jun, 2023
(Expiration: May, 2033)
|
ZAKLADY FARMACEUTYCZNE POLPHARMA
(and 1 more)
| |
| EP3393276B1 | High Integrity Encapsulation Product | MCCORMICK AND CO INC |
02 Jun, 2023
(Expiration: Dec, 2036)
|
FIRMENICH
| |
| EP3883393B1 | Nutritional Composition Comprising 2'Fucosyllactose And Dietary Butyrate | NUTRICIA NV |
02 Jun, 2023
(Expiration: Jun, 2040)
|
FRIESLANDCAMPINA NEDERLAND
(and 3 more)
| |
| EP2906301B1 | Aqueous Wax Dispersions And Hair Styling Compositions Containing Them | LOREAL SA |
01 Jun, 2023
(Expiration: Oct, 2033)
|
HENKEL
| |
| EP3694483B1 | Sulfate Free Clear Personal Cleansing Composition Comprising Low Inorganic Salt | PROCTER AND GAMBLE CO |
31 May, 2023
(Expiration: Oct, 2038)
|
BEIERSDORF
(and 7 more)
| |
| EP3463360B1 | Atropine-Containing Aqueous Composition | SANTEN PHARMACEUTICAL CO LTD |
31 May, 2023
(Expiration: May, 2037)
|
SANTARELLI
(and 1 more)
| |
| EP3833335B1 | Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate | INTAS PHARMACEUTICALS LTD |
30 May, 2023
(Expiration: Jul, 2040)
|
ELKINGTON AND FIFE
| |
| EP3478367B1 | Fragrance Compositions And Methods Of Use Thereof | TAKASAGO INTERNATIONAL CORP |
30 May, 2023
(Expiration: Jun, 2037)
|
HENKEL
| |
| EP3597216B1 | Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof | ER SQUIBB AND SONS LLC |
24 May, 2023
(Expiration: Aug, 2029)
|
STRAWMAN
(and 4 more)
| |
| EP3342782B1 | Optimized Fc Variants | XENCOR INC |
17 May, 2023
(Expiration: May, 2025)
|
JAMES POOLE
| |
| EP3407880B1 | Neurodevelopmental Disorder Therapy | ANAVEX LIFE SCIENCES CORP |
17 May, 2023
(Expiration: Jan, 2037)
|
SANDOZ
| |
| EP3324937B1 | Ready-To-Use Bortezomib Solution | STADA ARZNEIMITTEL AG |
16 May, 2023
(Expiration: Jul, 2036)
|
NEDERLANDSCH OCTROOIBUREAU
(and 6 more)
| |
| EP3386475B1 | Composition For Cleansing Keratin Materials With Improved Rinsing Properties | LOREAL SA |
12 May, 2023
(Expiration: Dec, 2035)
|
HENKEL
| |
| EP3532017B1 | Product Composition Comprising A Discrete Particle And An Aqueous Base Composition | PROCTER AND GAMBLE CO |
11 May, 2023
(Expiration: Apr, 2038)
|
HENKEL
| |
| EP3524595B1 | High-Purity Quinoline Derivative And Method For Manufacturing Same | EISAI R&D MANAGEMENT CO LTD |
10 May, 2023
(Expiration: Aug, 2035)
|
AECHTER
(and 8 more)
| |
| EP2645997B1 | Once Daily Formulation Of Lacosamide | UCB PHARMA GMBH |
10 May, 2023
(Expiration: Dec, 2031)
|
GENERICS UK
| |
| EP3375291B1 | A Method Of Inhibiting Isomerization Of A Reducing Saccharide Upon Thermal Treatment | CHR HANSEN HMO GMBH |
10 May, 2023
(Expiration: Mar, 2037)
|
GLYCOM
(and 1 more)
| |
| EP2723303B1 | Dental Restoration, Method For Its Production And Ingot | FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV |
10 May, 2023
(Expiration: Jun, 2032)
|
IVOCLAR VIVADENT
| |
| EP3795137B1 | Electrostatically Sprayable Cosmetic Formulation | IONIQ SKINCARE GMBH AND CO KG |
10 May, 2023
(Expiration: Sep, 2039)
|
LOREAL
| |
| EP3716992B1 | Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders | REGENERON PHARMACEUTICALS INC |
10 May, 2023
(Expiration: Nov, 2038)
|
MAIWALD
(and 3 more)
| |
| EP3866935B1 | Method Of Reducing Perspiration | UNILEVER GLOBAL IP LTD |
10 May, 2023
(Expiration: Oct, 2039)
|
THE PROCTER & GAMBLE
| |
| EP3448416B1 | Semaglutide In Cardiovascular Conditions | NOVO NORDISK AS |
09 May, 2023
(Expiration: Apr, 2037)
|
ADALVO
(and 7 more)
| |
| EP2359858B1 | Nutritional Composition Comprising Indigestible Oligosaccharides | NUTRICIA NV |
09 May, 2023
(Expiration: Aug, 2025)
|
FRIESLANDCAMPINA NEDERLAND
(and 1 more)
| |
| EP2413971B1 | Plant Fiber Product And Method For Its Manufacture | WINNINGTON AB |
09 May, 2023
(Expiration: Apr, 2029)
|
PHILIP MORRIS PRODUCTS
| |
| EP3560498B1 | Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor | NOVARTIS AG |
09 May, 2023
(Expiration: Oct, 2030)
|
STADA ARZNEIMITTEL
(and 1 more)
| |
| EP3749339B1 | Marine Protein Hydrolysate With Low Fluoride And Trimethylamin Content | AKER BIOMARINE ANTARCTIC AS |
03 May, 2023
(Expiration: Jan, 2039)
|
RIMFROST
| |
| EP3209308B1 | Activated Bifidobacteria And Methods Of Use Thereof | EVOLVE BIOSYSTEMS INC |
03 May, 2023
(Expiration: Oct, 2035)
|
SOCIT DES PRODUITS NESTL
| |
| EP3266306B1 | Impregnated Textile Fabric Providing Effective Delivery Of An Alcoholic Impregnant | SCHUELKE AND MAYR GMBH |
02 May, 2023
(Expiration: Jun, 2037)
|
B BRAUN MELSUNGEN
(and 4 more)
| |
| EP3653221B1 | Anti-Pvrig Antibodies And Methods Of Use | COMPUGEN LTD |
02 May, 2023
(Expiration: Feb, 2036)
|
ZACCO DENMARK
(and 1 more)
| |
| EP3097923B1 | Redirected, Genetically-Engineered T Regulatory Cells And Their Use In Suppression Of Autoimmune And Inflammatory Disease | YEDA RESEARCH AND DEVELOPMENT CO LTD |
27 Apr, 2023
(Expiration: Jan, 2028)
|
JG OPPOSITIONS
| |
| EP3708668B1 | Artificial Nucleic Acid Molecules For Improved Protein Expression | CUREVAC AG |
27 Apr, 2023
(Expiration: Dec, 2035)
|
SANOFI
(and 3 more)
| |
| EP3206693B1 | Prostaglandin Conjugates And Derivatives For Treating Glaucoma And Ocular Hypertension | ALCON INC |
27 Apr, 2023
(Expiration: Oct, 2035)
|
STADA ARZNEIMITTEL
| |
| EP2985026B1 | Pharmaceutical Delivery Systems For Hydrophobic Drugs And Compositions Comprising Same | CLARUS THERAPEUTICS INC |
26 Apr, 2023
(Expiration: Apr, 2026)
|
AERA
| |
| EP3845215B1 | Oral Solutions Comprising Lisdexamfetamine Salts | LABOMED PHARMACEUTICAL COMPANY SA |
26 Apr, 2023
(Expiration: Dec, 2039)
|
APPLEYARD LEES
| |
| EP3599898B1 | Liquid Nutritional Compositions Containing Oxidizable Fish Oil, Rosmarinic Acid And Ferric Iron | ABBOTT LABORATORIES |
26 Apr, 2023
(Expiration: Mar, 2038)
|
FRESENIUS KABI DEUTSCHLAND
| |
| EP2745849B1 | Polydeoxyribonucleotides Composition And Uses Thereof | ARCHIMEDES SRL |
26 Apr, 2023
(Expiration: Dec, 2033)
|
WITTHOFF JAEKEL STEINECKE PATENTANWLTE PARTG MBB
| |
| EP3103476B1 | Antibodies Against A Proliferating Inducing Ligand (April) | ADURO BIOTECH HOLDINGS EUROPE BV |
25 Apr, 2023
(Expiration: Feb, 2030)
|
ZWICKER SCHNAPPAUF & PARTNER PATENTANWLTE PARTG MBB
| |
| EP2968208B1 | Treatment Of Cataplexy | JAZZ PHARMACEUTICALS IRELAND LTD |
20 Apr, 2023
(Expiration: Mar, 2034)
|
SANDOZ
| |
| EP2981255B1 | Therapeutic Uses Of Empagliflozin | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
20 Apr, 2023
(Expiration: Apr, 2034)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 9 more)
| |
| EP3785702B1 | Microparticulate Varenicline Citrate | ALFRED E TIEFENBACHER GMBH AND CO KG |
19 Apr, 2023
(Expiration: Mar, 2040)
|
GENERICS UK
| |
| EP2477648B1 | Synergistic Anti-Cd47 Therapy For Hematologic Cancers | LELAND STANFORD JUNIOR UNIVERSITY |
19 Apr, 2023
(Expiration: Sep, 2030)
|
JG OPPOSITIONS
| |
| EP2397142B1 | Use Of Dpp Iv Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
19 Apr, 2023
(Expiration: May, 2027)
|
ZAKLADY FARMACEUTYCZNE POLPHARMA
(and 4 more)
| |
| EP2611467B1 | Small Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
17 Apr, 2023
(Expiration: Aug, 2031)
|
SANOFI
(and 4 more)
| |
| EP2642876B1 | Oligosaccharide Mixture And Food Product Comprising This Mixture, Especially Infant Formula | SOCIETE DES PRODUITS NESTLE SA |
13 Apr, 2023
(Expiration: Nov, 2031)
|
NUTRICIA
| |
| EP3256099B1 | Cosmetic Composition Containing Linear Alpha-Olefin Sulfonates, Anionic Surfactants, And Non-Ionic And/Or Amphoteric Surfactants, And Cosmetic Treatment Method | LOREAL SA |
11 Apr, 2023
(Expiration: Dec, 2035)
|
THE PROCTER & GAMBLE
| |
| EP3768304B1 | Compositions And Methods For Increasing Or Enhancing Transduction Of Gene Therapy Vectors And For Removing Or Reducing Immunoglobulins | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM |
06 Apr, 2023
(Expiration: Jul, 2039)
|
GATESIP
(and 5 more)
| |
| EP3725810B1 | Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer | TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH |
06 Apr, 2023
(Expiration: May, 2033)
|
MAIWALD
(and 1 more)
| |
| EP3773511B1 | An Oral Tablet For Induced Saliva Generation | FERTIN PHARMA AS |
06 Apr, 2023
(Expiration: May, 2039)
|
ROQUETTE FRRES
| |
| EP3442489B1 | Sunscreen Formulations Comprising An Oleosome Suspension And An Acidic Buffering System | BOTANECO INC |
31 Mar, 2023
(Expiration: Apr, 2037)
|
CARGILL
| |
| EP3782611B1 | Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof | CELGENE CORP |
31 Mar, 2023
(Expiration: May, 2029)
|
SANDOZ
(and 4 more)
| |
| EP3256100B1 | Cosmetic Composition Containing Linear Olefin Sulfonates, Non-Oxyalkylated Anionic Surfactants, And Non-Ionic And/Or Amphoteric Surfactants, And Cosmetic Treatment Method | LOREAL SA |
28 Mar, 2023
(Expiration: Dec, 2035)
|
KAO GERMANY
(and 1 more)
| |
| EP3122870B1 | Methods And Genetic Systems For Cell Engineering | GINKGO BIOWORKS INC |
28 Mar, 2023
(Expiration: Mar, 2035)
|
POTTER CLARKSON
(and 1 more)
| |
| EP3615148B1 | Compositions With A Thickening Polymer | PROCTER AND GAMBLE CO |
27 Mar, 2023
(Expiration: Apr, 2038)
|
HENKEL
(and 1 more)
| |
| EP3773498B1 | Liquid Pharmaceutical Formulation | PROJECT PHARMACEUTICS GMBH |
22 Mar, 2023
(Expiration: Mar, 2039)
|
ONCOPEPTIDES
| |
| EP3265115B1 | Uses Of Pthrp Analogue In Reducing Fracture Risk | RADIUS HEALTH INC |
21 Mar, 2023
(Expiration: Mar, 2036)
|
AERA
| |
| EP3895712B1 | Engineered Natural Killer Cells And Uses Thereof | ONK THERAPEUTICS LTD |
21 Mar, 2023
(Expiration: Dec, 2037)
|
AMMELBURG
| |
| EP3638375B1 | Hair Composition Having Improved Rinsing Properties | UNILEVER GLOBAL IP LTD |
21 Mar, 2023
(Expiration: Jun, 2038)
|
HENKEL
| |
| EP3253865B1 | Methods For Enhancing Efficacy Of Therapeutic Immune Cells | NATIONAL UNIVERSITY OF SINGAPORE |
21 Mar, 2023
(Expiration: Feb, 2036)
|
PATENT BOUTIQUE
| |
| EP3218061B1 | Carmustine Pharmaceutical Composition | NAVINTA III INC |
17 Mar, 2023
(Expiration: Nov, 2035)
|
BRAND MURRAY FULLER
| |
| EP3601363B1 | Alt-803 In Combination With Anti-Cd38 Antibody For Cancer Therapies | ALTOR BIOSCIENCE CORP |
15 Mar, 2023
(Expiration: Mar, 2038)
|
CYTUNE PHARMA
| |
| EP2883531B1 | Bleaching And Coloring Composition For Hair | KAO CORP |
14 Mar, 2023
(Expiration: Dec, 2033)
|
LOREAL
| |
| EP3542646B1 | Seaweed-Based Powder | CARGILL INC |
08 Mar, 2023
(Expiration: Mar, 2039)
|
CP KELCO APS
| |
| EP3107548B8 | Dry Powder Formulations For Inhalation | OTITOPIC INC |
08 Mar, 2023
(Expiration: Feb, 2035)
|
GENERICS UK
| |
| EP2872081B1 | Systems And Methods For Corneal Cross-Linking With Pulsed Light | AVEDRO INC |
07 Mar, 2023
(Expiration: Oct, 2032)
|
DEHNS
| |
| EP2903618B1 | Rho Kinase Inhibitors | KADMON CORP LLC |
28 Feb, 2023
(Expiration: Oct, 2033)
|
ELKINGTON AND FIFE
(and 1 more)
| |
| EP3448435B1 | Protein Based Excipient For Active Pharmaceutical Ingredients | ROUSSELOT BV |
28 Feb, 2023
(Expiration: Apr, 2037)
|
EVONIK OPERATIONS
(and 1 more)
| |
| EP3721868B1 | Ophthalmic Suspension Composition | BAUSCH AND LOMB INC |
28 Feb, 2023
(Expiration: Jan, 2036)
|
SANDOZ
| |
| EP3970742B1 | Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
27 Feb, 2023
(Expiration: Aug, 2031)
|
JG OPPOSITIONS
(and 4 more)
| |
| EP3368572B9 | Anti-Pd-1 Antibodies And Compositions | SYMPHOGEN AS |
24 Feb, 2023
(Expiration: Sep, 2036)
|
SANOFI
| |
| EP3439637B1 | Process For Mesalazine Solid Formulations | SOFAR SPA |
22 Feb, 2023
(Expiration: Apr, 2037)
|
ELKINGTON AND FIFE
| |
| EP3981427B9 | Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
21 Feb, 2023
(Expiration: Aug, 2031)
|
SANOFI
(and 4 more)
| |
| EP3681483B1 | Process For Lyophilized Pharmaceutical Formulation Of A Therapeutic Protein | AMGEN INC |
20 Feb, 2023
(Expiration: Sep, 2038)
|
WITHERS & ROGERS
(and 2 more)
| |
| EP3505635B1 | Widespread Gene Delivery To Motor Neurons Using Peripheral Injection Of Aav Vectors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS |
17 Feb, 2023
(Expiration: Oct, 2028)
|
BEZZUBOVA
| |
| EP3733617B1 | Low-Melting Glass Ceramic | VITA ZAHNFABRIK H RAUTER GMBH AND CO KG |
17 Feb, 2023
(Expiration: May, 2039)
|
RIECK
| |
| EP3357911B1 | Prolyl Hydroxylase Inhibitors And Methods Of Use | AKEBIA THERAPEUTICS INC |
13 Feb, 2023
(Expiration: Jun, 2027)
|
FIBROGEN
| |
| EP3568119B1 | Liquid Composition Comprising Hair Direct Dyes And One Or More Diols | KAO GERMANY GMBH |
08 Feb, 2023
(Expiration: Nov, 2037)
|
HENKEL
(and 1 more)
| |
| EP3490575B1 | Plant Extract Highly Concentrated In Safranal, Production Method And Uses Thereof | ACTIVINSIDE SAS |
06 Feb, 2023
(Expiration: Jul, 2037)
|
PHARMACTIVE BIOTECH PRODUCTS
| |
| EP3059009B1 | Process For The Storage Of Refreshing Agents | SYMRISE AG |
03 Feb, 2023
(Expiration: Feb, 2035)
|
BASF
| |
| EP3261651B1 | Chimeric Antigen Receptors (Cars) Targeting Hematologic Malignancies, Compositions And Methods Of Use Thereof | ICELL GENE THERAPEUTICS LLC |
03 Feb, 2023
(Expiration: Feb, 2036)
|
JAMES POOLE
(and 2 more)
| |
| EP3297605B1 | Topical Pharmaceutical Compositions | DERMAVANT SCIENCES GMBH |
03 Feb, 2023
(Expiration: May, 2036)
|
SANDOZ
| |
| EP3426226B1 | Ophthalmological Composition | URSAPHARM ARZNEIMITTEL GMBH |
02 Feb, 2023
(Expiration: Mar, 2037)
|
BAUSCH LOMB IRELAND
(and 2 more)
| |
| EP3558218B1 | Hair Lightening Composition Comprising Hydrogen Peroxide, A Peroxygenated Salt, A Bicarbonate And At Least One Polyphosphorus Derivative | LOREAL SA |
02 Feb, 2023
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP3366775B1 | Modified Rnai Agents | ALNYLAM PHARMACEUTICALS INC |
27 Jan, 2023
(Expiration: Nov, 2032)
|
AWA SWEDEN
| |
| EP3492073B1 | Oral Mucosa Application Material And Method For Producing Same | RITAPHARMA CO LTD |
27 Jan, 2023
(Expiration: Jul, 2037)
|
CONTIPRO
| |
| EP3718565B1 | Respiratory Virus Vaccines | MODERNATX INC |
27 Jan, 2023
(Expiration: Oct, 2036)
|
PFIZER
(and 3 more)
| |
| EP3169304B1 | Sprayable Sunscreen Composition With Oil Beads | LOREAL SA |
26 Jan, 2023
(Expiration: Jul, 2034)
|
BEIERSDORF
| |
| EP3403659B1 | Process, Tube And Device For The Preparation Of Wound Healant Composition | REGEN LAB SA |
26 Jan, 2023
(Expiration: Mar, 2031)
|
ESTAR
| |
| EP3042645B1 | Dental Composites With Improved Storage Stability | IVOCLAR VIVADENT AG |
26 Jan, 2023
(Expiration: Jan, 2035)
|
M DEUTSCHLAND DE M INNOVATIVE PROPERTIES
| |
| EP3585378B1 | Flavanones For Use In Treating Visceral Hypersensitivity | BIOACTOR BV |
26 Jan, 2023
(Expiration: Feb, 2038)
|
ZBM PATENTS
| |
| EP3265122B1 | Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer | EISAI R&D MANAGEMENT CO LTD |
23 Jan, 2023
(Expiration: Mar, 2036)
|
KNIG SZYNKA TILMANN VON RENESSE
(and 3 more)
| |
| EP3656860B1 | Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof | ALNYLAM PHARMACEUTICALS INC |
20 Jan, 2023
(Expiration: Jun, 2032)
|
GRNECKER PATENT UND RECHTSANWLTE PARTG MBB
| |
| EP3178490B1 | Rsv F Protein Compositions And Methods For Making Same | GLAXOSMITHKLINE BIOLOGICALS SA |
20 Jan, 2023
(Expiration: Jul, 2030)
|
PFIZER
(and 1 more)
| |
| EP3679915B1 | Flavivirus Vaccines | SANOFI PASTEUR BIOLOGICS LLC |
20 Jan, 2023
(Expiration: Jan, 2023)
|
TAKEDA
| |
| EP3606511B1 | Pharmaceutical Composition Comprising Lenvatinib Mesylate | SYNTHON BV |
18 Jan, 2023
(Expiration: Apr, 2038)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP3166570B1 | Two-Component Self-Adhesive Dental Composition, Process Of Production And Use Thereof | 3M INNOVATIVE PROPERTIES CO |
17 Jan, 2023
(Expiration: Jul, 2035)
|
KULZER
| |
| EP3576711B1 | Personal Care Composition | PROCTER AND GAMBLE CO |
13 Jan, 2023
(Expiration: Feb, 2038)
|
EDGEWELL PERSONAL CARE BRANDS
| |
| EP3199174B1 | Uses Of Neuregulin In Preventing, Treating Or Delaying Ventricular Arrhythmia, And Composition Thereof | ZENSUN SHANGHAI SCIENCE AND TECHNOLOGY LTD |
13 Jan, 2023
(Expiration: Sep, 2035)
|
STRAWMAN
| |
| EP3694482B1 | Sulfate Free Personal Cleansing Composition Comprising Low Inorganic Salt | PROCTER AND GAMBLE CO |
12 Jan, 2023
(Expiration: Oct, 2038)
|
UNILEVER UNILEVER
(and 6 more)
| |
| EP3699162B1 | Heterodimers Of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS INC |
10 Jan, 2023
(Expiration: Nov, 2027)
|
TELIX INNOVATIONS
| |
| EP3238737B1 | Means And Methods For Counteracting Muscle Disorders | LEIDS UNIVERSITAIR MEDISCH CENTRUM LUMC |
09 Jan, 2023
(Expiration: Oct, 2028)
|
MAIWALD
(and 1 more)
| |
| EP3773494B1 | Nicotine Pouch Composition And Pouch Comprising Such | NCP NEXTGEN AS |
06 Jan, 2023
(Expiration: Jun, 2040)
|
NICOVENTURES TRADING
| |
| EP3330279B1 | Method For Purifying Composition Comprising Antibodies With Anionic Polymer | CHUGAI PHARMACEUTICAL CO LTD |
05 Jan, 2023
(Expiration: Jul, 2036)
|
NEUEFEIND
| |
| EP3345602B1 | Rapamycin Derivative For Treating Advanced Solid Tumours | NOVARTIS PHARMA AG |
04 Jan, 2023
(Expiration: Feb, 2022)
|
STADA ARZNEIMITTEL
(and 2 more)
|